1. A pharmaceutical composition comprising an insulin derivative selected from
the group consisting of
I A14E, B16H, B25H, B29K((N£-Eicosanedioyl-YGIu-[2-(2-{2-[2-(2-aminoethoxy)-
ethoxy]acetylamino}ethoxy)ethoxy]acetyl)), desB30 human insulin (Compound 1);
A14E, B16H, B25H, B29K(N£-Hexadecandioyl-YGIu), desB30 human insulin (Compound 2);
A14E, B16H, B25H, B29K(N£-Eicosanedioyl-YGIu), desB30 human insulin i (Compound 3); and
A14E, B25H, desB27, B29K(N£-Octadecandioyl-YGIu), desB30 human insulin (Compound 4); and further comprising
of from about 1 to about 2% (weight/weight) of glycerol; of from about 45 to
about 75 mM of phenol; of from about 0 to about 19 mM of m-cresol; of from about 1.5
> to about 2.5 moles of zinc ions per six moles of said insulin derivative; not more than
about 75 mM of sodium chloride; and having a pH value in the range of from 7.2 to 8.0 .
2. The pharmaceutical composition according to claim 1, wherein the insulin
derivative is A14E, B16H, B25H, B29K((N£-Eicosanedioyl-YGIu-[2-(2-{2-[2-(2-
i aminoethoxy)ethoxy]acetylamino}ethoxy)ethoxy]acetyl)), desB30 human insulin (Compound 1).
3. The pharmaceutical composition according to either one of claims 1-2,
wherein the amount of insulin derivative is in the range of from about 3.5 to about 5.0
i mM .
4. The pharmaceutical composition according to either one of claims 1-2,
comprising of from about 1 to about 2% (weight/weight) of glycerol.
i 5. The pharmaceutical composition according to either one of claims 1-2,
comprising of from about 45 to about 75 mM of phenol, such as from about 55 mM to about 65 mM of phenol; or comprsing of 50 mM, 51 mM, 52 mM, 53 mM, 54 mM, 55 mM, 56 mM, 57 mM, 58 mM, 59 mM, 60 mM, 61 mM, 62 mM, 63 mM, 64 mM, 65 mM, 66 mM, 67 mM, 68 mM, 69 mM, or 70 mM of phenol.
6. The pharmaceutical composition according to either one of claims 1-2, comprising of from about 0 to about 19 mM of m-cresol, such as from about 0 mM to about 15 mM of m-cresol; or comprising of 0 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6

mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, or 15 mM of m-cresol.
7. The pharmaceutical formulation according to either one of claims 1-2, comprising of from about 1.5 to about 2.5 moles of zinc ions per six moles of insulin derivative.
8. The pharmaceutical composition according to either one of claims 1-2, comprising less than about 25 mM of sodium chloride.
9. The pharmaceutical composition according to either one of claims 1-2, having
a pH value in the range of from 7.2 to 8.0.
10. The pharmaceutical composition according to either one of claims 1-2,
comprising
of from about 4.0 to about 4.5 mM of insulin derivative; of from about 1 to about 2% (weight/weight) of glycerol; of from about 50 to about 70 mM of phenol;
of from about 0 to about 15 mM of m-cresol; of from about 2.0 to about 2.5 moles of zinc ions per six moles of insulin derivative;
no more than about 25 mM of sodium chloride; and having a pH value in the range of from 7.2 to 7.6.
11. The pharmaceutical composition according to either one of claims 1-2,
comprising
of about 4.2 mM of insulin derivative;
of about 1.5% (weight/weight) of glycerol;
of about 60 mM of phenol;
of about 0 mM of m-cresol;
of about 2.2 moles of zinc ions per six moles of insulin derivative;
of about 20 mM of sodium chloride; and
having a pH value of about 7.4.
12. The pharmaceutical composition according to either one of claims 1-2,
comprising
of about 4.2 mM of insulin derivative;
of about 1.5% (weight/weight) of glycerol;
of about 60 mM of phenol;

of about 10 mM of m-cresol;
of about 2.2 moles of zinc ions per six moles of insulin derivative; of about 20 mM of sodium chloride; and having a pH value of about 7.4.
13. The pharmaceutical composition according to any one of the preceding claims, further comprising semaglutide.
14. The pharmaceutical composition according to claim 13, wherein the amount of semaglutide is in the range of from about 0.30 to about 0.70 mM .
15. The pharmaceutical composition according to claim 1, for use as a
medicament for the treatment of a metabolic disorder.